OCUGEN, INC. Gain (Loss) on Termination of Lease
OCUGEN, INC. (OCGN) reported Gain (Loss) on Termination of Lease of -$270.00 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2019-08-09
- OCUGEN, INC. gain (loss) on termination of lease for the quarter ending 2019-06-30 was -$270.00K.
| Period end | Gain (Loss) on Termination of Lease 3 month | Gain (Loss) on Termination of Lease 6 month |
|---|---|---|
| 2019-06-30 | -$270.00K 10-Q · filed 2019-08-09 | -$270.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |